Latest Comments

CRISPR CAS 9 genome editing heralds a revolution in healthcare

CRISPR CAS 9 genome editing heralds a revolution in healthcare

Personalised medicine: a paradigm shift in treatment

Personalised medicine: a paradigm shift in treatment

Pharmacoeconomics: a crushing reality in today’s industry

Pharmacoeconomics: a crushing reality in today’s industry

Ohr Pharmaceuticals is determined to show efficacy for Squalamine despite setbacks

Ohr Pharmaceuticals is determined to show efficacy for Squalamine despite setbacks

Despite widespread legalisation, federal regulations are keeping cannabis research under wraps

Despite widespread legalisation, federal regulations are keeping cannabis research under wraps

WHO appeal for new antibiotics lacks necessary incentives

WHO appeal for new antibiotics lacks necessary incentives

Emflaza launch in the US on hold due to pricing outrage

Emflaza launch in the US on hold due to pricing outrage

Biosimilar development: the incentives and challenges

Biosimilar development: the incentives and challenges

A novel mosquito vaccine promises broad protection, but can it deliver?

A novel mosquito vaccine promises broad protection, but can it deliver?

Loosening FDA approval standards would do more harm than good

Loosening FDA approval standards would do more harm than good

A chemotherapy-free future for breast cancer?

A chemotherapy-free future for breast cancer?

A brighter future for rheumatoid arthritis patients?

A brighter future for rheumatoid arthritis patients?

Will FDA guidance on interchangeability help or hinder biosimilar market growth?

Will FDA guidance on interchangeability help or hinder biosimilar market growth?

Low Drug Compliance in Lupus: Are Patients Really to Blame?

Low Drug Compliance in Lupus: Are Patients Really to Blame?

Will a focus on oncology bring blockbuster success?

Will a focus on oncology bring blockbuster success?

The emergence of oncology biosimilars

The emergence of oncology biosimilars

CDK4/6 inhibitor rivalry in breast cancer begins

CDK4/6 inhibitor rivalry in breast cancer begins

BMS to have their cake and eat it with Keytruda settlement

BMS to have their cake and eat it with Keytruda settlement

Roche’s Tecentriq pulls further ahead in metastatic bladder cancer

Roche’s Tecentriq pulls further ahead in metastatic bladder cancer

Keytruda data fuels debate over PD-L1 as a biomarker in metastatic bladder cancer

Keytruda data fuels debate over PD-L1 as a biomarker in metastatic bladder cancer

Elagolix launch is welcome, but it won't be a cure-all for endometriosis

Elagolix launch is welcome, but it won't be a cure-all for endometriosis